At CRVBC 2025: Aging is circulating in your blood
All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins, pathogens and certain trafficking cells. Among these harmful substances are deleterious factors associated with aging, which can prematurely damage different tissues. The big question is what are those factors that mediate such effects, and what can be done to prevent them. The 11th Cardiac Regeneration and Vascular Biology Conference, held on the Island of San Servolo, Venice, from June 30 to July 2, 2025, included presentations, oral sessions and posters addressing the impact of aging on the cardiovascular system.

Chemotherapy-induced mutations are not universal phenomenon
The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not all, of these agents cause mutations and premature aging of normal blood cells.

At CRVBC 2025: Aging is circulating in your blood
All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins, pathogens and certain trafficking cells. Among these harmful substances are deleterious factors associated with aging, which can prematurely damage different tissues. The big question is what are those factors that mediate such effects, and what can be done to prevent them. The 11th Cardiac Regeneration and Vascular Biology Conference, held on the Island of San Servolo, Venice, from June 30 to July 2, 2025, included presentations, oral sessions and posters addressing the impact of aging on the cardiovascular system.
Chemotherapy-induced mutations are not universal phenomenon
The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not all, of these agents cause mutations and premature aging of normal blood cells.
Other news to note for July 4, 2025
Additional early-stage research and drug discovery news in brief.
Brightpath’s BP-2202 designated orphan drug for multiple myeloma
Brightpath Biotherapeutics Co. Ltd.’s iPS cell-derived BCMA CAR-natural killer T cell therapy candidate has been awarded orphan drug designation by the FDA for the treatment of multiple myeloma.
Innocare’s ICP-B794 gains IND clearance in China
Innocare Pharma Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of the B7-H3 targeted antibody-drug conjugate.
Jiangsu Vcare Pharmatech patents new ER degradation inducers
Jiangsu Vcare Pharmatech Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor (ER) degradation inducers.
IL-24S/IL-15 fusion ‘superkine’ induces apoptosis of GBM cells, promotes antitumor immunity
A recent study published in the Journal for Immunotherapy of Cancer has revealed a promising new approach for the treatment of glioblastoma (GBM), an aggressive and incurable form of primary brain cancer.

BioWorld Insider Podcast

Robert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.

Listen now

Conferences

Eccogene’s ECC-4703 leads to greater weight loss in preclinical studies
American Diabetes Association
Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an agonist of thyroid hormone receptor β (THR-β) and its metabolic impact on preclinical models of obesity...
[68Ga]NXK-44 radiotracer arises as a promising agent for RCC
New compound
Chinese researchers from Huazhong University of Science and Technology have developed a novel carbonic anhydrase IX (CAIX)-targeting radiotracer, [68Ga]NXK-44, for the imaging of hypoxic tumors and renal cell carcinoma (RCC).
GRWD-0715 blocks pathogenic T-cell activation in axial spondyloarthritis
Musculoskeletal
Researchers from Grey Wolf Therapeutics Ltd. presented the preclinical characterization of GRWD-0715, a selective ERAP1 inhibitor developed as a disease-modifying therapeutic approach aimed at preventing CD8+ T-cell activation and the subsequent tissue inflammation and damage associated with...
ASC-47 shows superior weight loss effect compared to semaglutide
American Diabetes Association
ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in healthy subjects and in patients with obesity, respectively.

Cancer

IL-12-expressing oncolytic virus shows promise for solid tumors
Immuno-oncology
A newly developed oncolytic virus, SKV-012, has demonstrated promising results in preclinical studies and a phase I clinical trial for the treatment of advanced solid tumors.

Infection

Bioversys, Shionogi in CHF529M lung infection collaboration
Clinical
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.

Pfizer discovers new nucleoprotein N inhibitors for RSV infection
Patents
Pfizer Inc. has described nucleoprotein N (respiratory syncytial virus [RSV]) inhibitors reported to be useful for the treatment of RSV infection.
New PZA-mimicking prodrugs for tuberculosis disclosed in University of Maryland patent
Patents
University of Maryland has divulged pyrazinamide (PZA)-mimicking prodrugs reported to be useful for the treatment of tuberculosis.

Neurology/psychiatric

Redox-sensitive PET tracer detects ROS-driven neuroinflammation
Conferences
Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter probe for imaging neuroinflammation in preclinical models of multiple sclerosis (MS). MS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by...
Shenzhen Bay Laboratory divulges new GPR139 agonists
Patents
Shenzhen Bay Laboratory has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of Parkinson’s disease, epilepsy, pain, depression, schizophrenia, substance abuse and dependence, post-traumatic stress and autism spectrum disorders.
Valo Health patents new S1P1 receptor agonists
Patents
Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis, systemic lupus erythematosus, ulcerative colitis, lymphopenia and Crohn’s disease.
MRT-6160 VAV1 molecular glue blocks EAE in preclinical models
Conferences
VAV1 is a guanine nucleotide exchange factor essential for T- and B-cell receptor signaling, with expression largely restricted to immune cells. Loss of VAV1, via CRISPR or genetic deletion, impairs effector functions in both T and B cells.
Encoding an entire mAb against TDP-43 into AAV to treat neurodegenerative diseases
Monoclonal antibody
Monoclonal antibodies show strong therapeutic potential against neurodegenerative diseases, but a major challenge is ensuring that they can arrive unharmed in the brain at sufficient concentrations. One way around this challenge is to vectorize the monoclonal antibody: encode it within a vector...

Endocrine/metabolic

Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity
Peptide
Protagonist Therapeutics Inc. has nominated PN-477 as a development candidate for the treatment of obesity.

Biomarkers

Metabolic markers to predict efficacy of immune checkpoint inhibitors in non-small-cell lung cancer
Cancer
Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of lung cancer involve non-small-cell lung cancer (NSCLC), in which therapy with immune checkpoint inhibitors (ICIs) can improve prognosis, yet up to 75% of patients fail to...

miR-7974 is a predictor of poor survival in ER+ breast cancer
Conferences
Estrogen receptor-positive (ER+) breast cancer remains a major challenge even with well-defined treatment options. The identification of reliable markers for early detection of the disease is crucial for improving patient outcomes.
Taurine aging biomarker story gets more complicated
Science
A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on Aging published on June 5, 2025, in Science has stated that the impact of taurine supplementation at delaying aging or treating aging-related conditions is context-dependent,...

Gastrointestinal

Engineered anti-IL-23 receptor antibody enables oral delivery to treat inflammatory bowel disease
Antibody
Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel disease in animal models.
Gut microbiome leads to metabolic and immune changes after transplant
Science
Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.
Korean scientists divulge new ADAMTS4 inhibitors for hepatic fibrosis
Patents
Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
New LPAM-1 antagonists disclosed in Dice Molecules patent
Patents
Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.
Gut microbiome leads to metabolic and immune changes after transplant
Science
Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the...
17β-HSD13 inhibitors described in Astrazeneca patent
Patents
Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.

podcast microphone, sound waves on purple background Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.

Recent episodes:

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription

Today's news in brief

BioWorld

BioWorld MedTech

BioWorld Asia

BioWorld Science

BioWorld Premium